title: Intratumoral Vascular Shunting: Biomarker of Clinical Outcome and Source of Circulating Tumor Cells?
abstract: Predicting which patients will benefit from radioembolization remains a challenge, as reliable prognostic indicators are not defined. Abnormal tumor vascular anatomy could not only impact the ability of cancer therapies to penetrate tumors, but may also contribute to a lesion's metastatic potential. Specifically, intratumoral vascular shunts could allow circulating tumor cells to initiate metastases by allowing them to gain access to distant sites in the body, bypassing capillary beds. Here, we describe how tumoral angiogenesis occurs and how intratumoral vascular shunts may form.
authors.affiliation: Divisions of *Interventional Radiology ‡Hematology/Oncology, Massachusetts General Hospital †Harvard Medical School, Boston, MA.
authors.forename: Amy R
authors.initials: AR
authors.lastname: Deipolyi
authors.forename: Andrew X
authors.initials: AX
authors.lastname: Zhu
authors.forename: Rahmi
authors.initials: R
authors.lastname: Oklu
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000098:blood supply* / Q000473:pathology / Q000628:therapy; D004621:Embolization, Therapeutic; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000628:therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000098:blood supply / Q000473:pathology / Q000628:therapy; D009360:Neoplastic Cells, Circulating; D009389:Neovascularization, Pathologic / Q000473:pathology* / Q000628:therapy; D013438:Sulfhydryl Compounds; D013668:Technetium Tc 99m Aggregated Albumin
chemical_list: D013438:Sulfhydryl Compounds; D013668:Technetium Tc 99m Aggregated Albumin; C082426:technetium Tc99m-mercaptoacetyl albumin